Motive and opportunity: <i>MYC</i> rearrangements in high-grade B-cell lymphoma with <i>MYC</i> and <i>BCL2</i> rearrangements (an LLMPP study)

Laura K. Hilton(BC Cancer Agency), David W. Scott, Waleed Alduaij(University of Manchester), Giorgio Inghirami(New York University), Pedro Farinha, Lisa M. Rimsza(World Wide Web Consortium), Wing C. Chan, Kerry J. Savage(BC Cancer Agency), Dennis D. Weisenburger(University of Nebraska Medical Center), Louis M. Staudt(National Institutes of Health), Laurie H. Sehn(BC Cancer Agency), Susana Ben‐Neriah(Apple (Israel)), Andreas Rosenwald(National Institutes of Health), Joo Y. Song(City of Hope), Elı́as Campo(Hospital Clínic de Barcelona), Brett Collinge, Philipp W. Raess(Oregon Health & Science University), Klaus Beiske(Oslo University Hospital), Timothy C. Greiner(Czech Academy of Sciences, Institute of Microbiology), Sarah L. Ondrejka(Cleveland Clinic), Christian Steidl(Spinal Cord Injury BC), Javeed Iqbal(TiGenix (Spain)), Andrew J. Mungall(Canada's Michael Smith Genome Sciences Centre), Graham W. Slack(BC Cancer Agency), Tomoko Miyata‐Takata(Spinal Cord Injury BC), Haya Shaalan(Simon Fraser University), James R. Cook, Andrew P. Weng(BC Cancer Agency), German Ott, Catalina Amador(University of Miami), Ryan D. Morin(Simon Fraser University), Jan Delabie, Merrill Boyle, Elaine S. Jaffe(Center for Cancer Research), Andrew L. Feldman(Mayo Clinic in Arizona), Barbara Meissner, George Wright(National Institutes of Health), Manuela Martins Cruz(Simon Fraser University), Stafania Pittaluga(National Institutes of Health), Kai Fu(Tianjin Medical University Cancer Institute and Hospital)
Blood
May 3, 2024
Cited by 35


Related Papers